Navigation Links
Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
Date:10/2/2007

Ranbaxy One of Few Companies to Offer Both Suspension and Tablet Forms

PRINCETON, N.J., Oct. 2 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Clarithromycin for Oral Suspension, USP, 125 mg/5 mL and 250 mg/5 mL. Ranbaxy is the first company to have been granted a generic approval for the Oral Suspension form along with Clarithromycin Tablets. Total annual market sales for Clarithromycin were $99.7 million with suspension sales totaling $25.3 million (IMS - MAT: June 2007).

"We are pleased to receive this FDA approval for Clarithromycin for Oral Suspension, an anti-infective agent that will add depth and breadth to our product line of anti-infectives that also includes Clarithromycin tablets. RPI will be in a position to offer both dosage forms for this molecule that will distinguish Ranbaxy in the market place. This approval further expands our product portfolio of affordable generic alternatives and will be shipped immediately to all classes of trade," according to Jim Meehan, Vice President of Sales and Distribution for RPI.

The Office of Generic Drugs, U.S. FDA, determined the Ranbaxy formulation to be bioequivalent and to have the same therapeutic effect as that of the reference listed drug Biaxin(R) Granules (Clarithromycin for Oral Suspension, USP), 125 mg/5 mL and 250 mg/5 mL of Abbott Laboratories.

Clarithromycin for oral suspension, USP, is indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in a number of conditions including: Pharyngitis/Tonsillitis, Community-Acquired Pneumonia, uncomplicated skin and skin structure infections and disseminated mycobacterial infections.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly own
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. SRL Ranbaxy offers quicker bird flu diagnostic test
11. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... (May 18, 2013) The use of a ... colonoscopy, according to new research presented today at ... begins days in advance of the procedure, includes ... to be taken at strict intervals. The better ... to see cancer and precancerous polyps in the ...
(Date:5/18/2013)... ground-breaking advance in colonoscopy technology signals the future ... at Digestive Disease Week (DDW). Additional research focuses ... and exploring safer methods for removing polyps. ... called a colonoscope to examine the colon. This ... to look for precancerous polyps called adenomas in ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...
(Date:5/18/2013)... KY (PRWEB) May 18, 2013 During ... hearing loss should consider the legal protections they have, ... when problems arise with their child’s treatment or hearing ... , Since 1927, the American Speech-Language-Hearing Association has used ... disorders and to promote treatment, such as cochlear implants, ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... The supervisory board of Celesio AG has today approved ... wholesaler Panpharma. This step into one of the most ... Celesio,s growth strategy. Celesio doesn,t plan to setup a ... about two years thoroughly analysing the Brazilian pharmaceutical market, ...
... mental stress not seen in those with high blood pressure, ... and other forms of mental stress cause dilation of the ... brain in healthy people, but this doesn,t occur in those ... researchers who used ultrasound imaging to monitor the carotid arteries ...
... , SACRAMENTO, Calif., July 10 After several months ... the chief executive officer of a leading statewide mental ... shop Psycho Donuts, will meet face to face to ... questionable business practices. , , Owners Kipp Berdiansky ...
... Aegis of Granada Hills has been named "Best Assisted Living ... their annual Readers Choice Awards. This is the second year in ... award. In voting, Aegis was a write-in candidate and received ... metro area to gain top status. , , ...
... 10 A sometimes fatal "superbug" is popping up in ... people live. It,s called methicillin-resistant Staphylococcus aureus, (MRSA "mer,-sa"). Health ... to slow its spread. , , "Physicians, health ... threat through the appropriate use of antibiotics, proper wound care ...
... more than half of patients reported improvement , FRIDAY, July ... asthma and other respiratory conditions shows promise in restoring a ... ability. , "More work needs to be done but, for ... an option worth trying," said Dr. Ronald Kuppersmith, clinical assistant ...
Cached Medicine News:Health News:Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma 2Health News:Blood Rush to the Brain When Angry Is a Good Sign 2Health News:There Is No Way to Sugar Coat These Donuts 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 3Health News:Drug Might Restore Sense of Smell 2Health News:Drug Might Restore Sense of Smell 3
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & General ... Conference on Thursday, May 30, 2013, in New ... The Company,s presentation is scheduled to begin at ... webcast. To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: